Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Vikings defensive backs coach and pass game coordinator Daronte Jones is interviewing with a second team for a possible promotion to defensive coordinator. After interviewing with the Chicago ...

It's not likely Sam Darnold returns to Minnesota, but the Vikings might not be closing the door just yet. NFC Wild Card Playoffs: Minnesota Vikings v Los Angeles Rams / Norm Hall/GettyImages The ...

Resurfacing after months of recovery, Minnesota Vikings quarterback J.J. McCarthy looks different. Seen on the Vikings sidelines during their final regular-season game, the former 10th overall ...

Former Vikings tight end Nick Muse signed with the Philadelphia Eagles' practice squad this week. Muse had been on Minnesota's practice squad this past season. He hadn't signed a reserve/futures ...

Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet aimed at treating metabolic disorders, such as obesity. The VENTURE-Oral Dosing Trial is a ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...